地诺单抗用法与用量

(Denosumab) is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Human RANKL mRNA is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts. So, what is the dosage of denosumab? Let’s find out.

Denosumab (Denosumab) can only be given by subcutaneous injection, not by intravenous infusion, intramuscular infusion, or intradermal injection. Giant cell tumor of bone: 120 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. Administer calcium and vitamin D appropriately to prevent hypocalcemia. Bone metastases from solid tumors: 120 mg subcutaneously in the upper arm, thigh, or abdomen every 4 weeks. Malignant hypercalcemia: 20 mg subcutaneously every 4 weeks, followed by 120 mg on days 8 and 15 during the first month of treatment. The medication is injected under the skin in the upper arm, thigh, or abdomen.

Nursing Mothers: It is not known whether denosumab (Denosumab) is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions from denosumab in nursing infants, the decision whether to discontinue breastfeeding or discontinue the drug should be made taking into account the importance of the drug to the mother. Based on animal studies in pregnant mice lacking the RANK/RANKL signaling pathway, which has shown altered maternal mammary gland maturation leading to impaired postpartum lactation, maternal exposure to denosumab during pregnancy may impair mammary gland development and lactation.

Pediatric Use: The safety and effectiveness of denosumab (denosumab) in pediatric patients have not been established. Treatment with denosumab (denosumab) may impair bone growth in children with open growth plates and may inhibit delayed eruption of permanent teeth.

Geriatric Use: In the trial, 1,260 patients (44%) who received denosumab were 65 years or older. No overall differences in safety or efficacy were observed between these patients and younger patients. For use in patients with renal impairment. In a trial of 55 patients without cancer and with varying degrees of renal function who received a single 60 mg dose of denosumab, patients with creatinine clearance less than 30 mL/min or receiving dialysis were at higher risk for severe hypocalcemia on denosumab than patients with normal renal function. The risk of hypocalcemia with the recommended dosage regimen of 120 mg every 4 weeks has not been evaluated in patients with creatinine clearance less than 30 mL/min or receiving dialysis.

The above is the usage and dosage of (Denosumab) provided by our medical companion travel. Patients must follow the doctor's instructions and take the medicine on time.

Recommended related hot articles: /newsDetail/74117.html